Celldex Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Celldex Therapeutics
CLDX Stock  USD 25.14  0.51  1.99%   
Celldex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Celldex Therapeutics' valuation are provided below:
Gross Profit
-214.1 M
Market Capitalization
1.7 B
Enterprise Value Revenue
432.4074
Revenue
2.6 M
Earnings Share
(3.38)
We have found one hundred twenty available fundamental signals for Celldex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Celldex Therapeutics prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 1.8 B in 2026. Enterprise Value is likely to rise to about 1.8 B in 2026

Celldex Therapeutics Total Revenue

7.68 Million

Check Celldex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Celldex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 5.8 M or Selling General Administrative of 42.1 M, as well as many indicators such as Price To Sales Ratio of 219, Dividend Yield of 0.0 or PTB Ratio of 2.38. Celldex financial statements analysis is a perfect complement when working with Celldex Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Celldex Stock
Check out the analysis of Celldex Therapeutics Correlation against competitors.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Celldex Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets956.8 M911.2 M370.4 M
Slightly volatile
Other Current Liabilities42 M40 M19.4 M
Slightly volatile
Total Current Liabilities47.7 M45.4 M24 M
Slightly volatile
Property Plant And Equipment Net6.1 M9.5 M8.1 M
Very volatile
Cash31.1 M32.6 M39.2 M
Pretty Stable
Non Current Assets Total31.5 M52 M56 M
Very volatile
Cash And Short Term Investments875.8 M834.1 M305 M
Slightly volatile
Common Stock Shares Outstanding77.8 M74.1 M26.4 M
Slightly volatile
Liabilities And Stockholders Equity956.8 M911.2 M370.4 M
Slightly volatile
Non Current Liabilities Total6.4 M6.7 M17.2 M
Pretty Stable
Other Current Assets25.6 M24.4 M6.9 M
Slightly volatile
Other Stockholder Equity2.8 B2.6 B1.2 B
Slightly volatile
Total Liabilities26.3 M52.1 M39.5 M
Very volatile
Property Plant And Equipment Gross38.3 M36.5 M16.8 M
Slightly volatile
Total Current Assets902.2 M859.2 M313 M
Slightly volatile
Net Receivables973.4 K805 K1.2 M
Slightly volatile
Non Currrent Assets Other11.8 M11.2 M2.8 M
Slightly volatile
Accounts Payable3.9 M3.8 M2 M
Slightly volatile
Short and Long Term Debt Total5 M4.4 M5 M
Slightly volatile
Short Term Debt3.1 M1.7 M3.2 M
Slightly volatile
Common Stock Total Equity65.1 K54 K63 K
Pretty Stable
Common Stock53.1 K59.4 K64.2 K
Pretty Stable
Intangible Assets27.1 M31.3 M33.6 M
Very volatile
Current Deferred Revenue10.3 M10.8 M11.1 M
Very volatile
Other Liabilities5.8 M6.1 M14.4 M
Very volatile
Other Assets88.9 K93.6 K438.6 K
Slightly volatile
Property Plant Equipment7.2 M7 M8 M
Pretty Stable
Short Term Investments841.5 M801.5 M267.1 M
Slightly volatile
Net Tangible Assets361.1 M343.9 M189.4 M
Slightly volatile
Long Term Debt Total5.9 M5.2 M6.1 M
Slightly volatile
Capital Surpluse1 B1.8 B1 B
Slightly volatile
Non Current Liabilities Other3 M3.1 M15.7 M
Pretty Stable
Short and Long Term Debt5 M5.2 M4.2 M
Slightly volatile
Net Invested Capital902 M859.1 M353 M
Slightly volatile
Long Term Investments1.4 M1.6 M1.8 M
Slightly volatile
Net Working Capital854.5 M813.8 M278.3 M
Slightly volatile
Capital Stock44.8 K75.9 K29.5 K
Slightly volatile
Capital Lease Obligations2.7 M3.4 M3.5 M
Slightly volatile

Celldex Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization2.4 M3.7 M3.4 M
Pretty Stable
Selling General Administrative42.1 M44.3 M23.8 M
Slightly volatile
Total Revenue7.7 M8.1 M6.5 M
Very volatile
Other Operating Expenses244 M232.4 M122 M
Slightly volatile
Total Operating Expenses32.2 M44.3 M45.9 M
Pretty Stable
Research Development197.5 M188.1 M89.1 M
Slightly volatile
Selling And Marketing Expenses11 B16.9 B14.2 B
Slightly volatile
Non Recurring3.8 M4 M13.8 M
Very volatile
Non Operating Income Net Other551.7 K580.8 K1.9 M
Pretty Stable
Interest Income4.3 M4.8 M3.6 M
Slightly volatile
Reconciled Depreciation3 M2.9 M4.3 M
Slightly volatile
Extraordinary Items15.3 M17.2 M18.8 M
Slightly volatile

Celldex Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation2.4 M3.7 M3.3 M
Very volatile
End Period Cash Flow31.8 M32.6 M39.8 M
Pretty Stable
Begin Period Cash Flow30.9 M40 M39.8 M
Very volatile
Total Cash From Financing Activities533 M507.7 M168 M
Slightly volatile
Stock Based Compensation29.3 M30.8 M19.5 M
Very volatile
Change To Netincome15.7 M11 M12.9 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio219209235
Pretty Stable
PTB Ratio2.382.513.2924
Pretty Stable
Days Sales Outstanding45.6232.7665.5947
Slightly volatile
Book Value Per Share12.6713.3433.778
Slightly volatile
Average Payables1.5 M2.6 M2.7 M
Very volatile
Stock Based Compensation To Revenue5.335.613.5991
Pretty Stable
Capex To Depreciation0.810.690.7034
Pretty Stable
PB Ratio2.382.513.2924
Pretty Stable
EV To Sales216205205
Slightly volatile
Payables Turnover47.3445.0831.1153
Slightly volatile
Sales General And Administrative To Revenue6.06.314.2874
Slightly volatile
Research And Ddevelopement To Revenue22.0220.9714.7273
Slightly volatile
Capex To Revenue0.240.250.3363
Very volatile
Cash Per Share12.312.9535.1878
Slightly volatile
Days Payables Outstanding7.968.3867.8389
Slightly volatile
Intangibles To Total Assets0.03750.03950.1877
Slightly volatile
Current Ratio17.8717.0211.6403
Slightly volatile
Tangible Book Value Per Share12.2112.8528.2778
Slightly volatile
Receivables Turnover18.029.0325.4098
Slightly volatile
Shareholders Equity Per Share12.6713.3433.778
Slightly volatile
Debt To Equity0.00560.00590.0346
Slightly volatile
Capex Per Share0.03260.03431.0757
Slightly volatile
Graham Net Net11.5412.1525.7693
Slightly volatile
Average Receivables328 K260.7 K243.1 K
Very volatile
Revenue Per Share0.120.130.9059
Slightly volatile
Interest Debt Per Share0.06470.06811.1287
Slightly volatile
Debt To Assets0.00530.00550.0265
Slightly volatile
Price Book Value Ratio2.382.513.2924
Pretty Stable
Days Of Payables Outstanding7.968.3867.8389
Slightly volatile
Ebt Per Ebit0.740.730.9052
Pretty Stable
Effective Tax Rate0.00350.00370.2318
Slightly volatile
Company Equity Multiplier1.570.951.2258
Slightly volatile
Long Term Debt To Capitalization0.05880.05090.0541
Slightly volatile
Total Debt To Capitalization0.00550.00580.0311
Slightly volatile
Debt Equity Ratio0.00560.00590.0346
Slightly volatile
Quick Ratio17.8717.0211.6433
Slightly volatile
Net Income Per E B T1.621.150.9988
Slightly volatile
Cash Ratio0.780.832.2393
Slightly volatile
Days Of Sales Outstanding45.6232.7665.5947
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.161.044
Pretty Stable
Price To Book Ratio2.382.513.2924
Pretty Stable
Fixed Asset Turnover0.930.981.0052
Slightly volatile
Debt Ratio0.00530.00550.0265
Slightly volatile
Price Sales Ratio219209235
Pretty Stable
Asset Turnover0.00970.01020.0363
Slightly volatile
Price Fair Value2.382.513.2924
Pretty Stable

Celldex Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.7 B1.4 B
Slightly volatile
Enterprise Value1.8 B1.7 B1.4 B
Slightly volatile

Celldex Fundamental Market Drivers

Celldex Upcoming Events

27th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Celldex Therapeutics Financial Statements

Celldex Therapeutics investors use historical fundamental indicators, such as Celldex Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Celldex Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue10.8 M10.3 M
Total Revenue8.1 M7.7 M
Cost Of Revenue188.1 M197.5 M
Stock Based Compensation To Revenue 5.61  5.33 
Sales General And Administrative To Revenue 6.31  6.00 
Research And Ddevelopement To Revenue 20.97  22.02 
Capex To Revenue 0.25  0.24 
Revenue Per Share 0.13  0.12 
Ebit Per Revenue(31.96)(30.36)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY